52w high/low | ₹83.6 / ₹38.1 |
P/E ratio | 14.05 |
Dividend | 0 |
ROE | 15.84 |
ROCE | 12.75 |
Face value | 10 |
Book value | ₹55.36Cr |
Market capital | ₹92.81Cr |
What is shareholding pattern? Who are shareholders?
What is a cash flow statement?
What is a balance sheet?
What is a profit and loss statement?
What are dividends?
What are bonuses?
Godavari Drugs is engaged in manufacturing drugs. Sulphamethoxazole (SMX), the main product of the company, is a widely used anti-bacterial drug enjoying good export demand. The company has expanded its SMX capacity from 540 tpa to 720 tpa, integrating backward into the manufacture of drug intermediates, sulphamethoxide (cap. : 450 tpa) and diethyl oxalate, DEO (cap. : 750 tpa), and diversifying into the manufacture of trimetroprim, TMP (cap. : 144 tpa). The diversification into TMP is beneficial as SMX and TMP are used in combination to treat a wide variety of infections. The backward integration into SMO and DEO will enhance value-addition.